microdosing tirzepatide vs semaglutide FITISH GLP-1 PROGRAM Microdosing GLP-1's for Weight Loss

Over the past couple of yearsspanning two administrationscoverage of GLP-1s for weight loss has been controversial: November 2024: the Biden administration proposed a major shift, allowing CMS to cover GLP-1s like Wegovy and Zepbound for weight loss

A modified approach works better: plain chicken broth with shredded chicken, protein-fortified applesauce, yogurt smoothies, and scrambled eggs made with just a touch of butter

Wu, X., Daniels, G., Lee, P

Around 64% of endocrinologists prescribe GLP-1 receptor agonists as second-line therapy, while semaglutide accounts for nearly 58% of prescriptions compared to 42% for liraglutide

This reflects the enhanced efficacy achieved through combination therapy, allowing therapeutic goals to be reached at lower individual compound doses